CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
- PMID: 31747563
- DOI: 10.1016/j.imlet.2019.11.007
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
Abstract
Chemokines are small molecules called "chemotactic cytokines" and regulate many processes like leukocyte trafficking, homing of immune cells, maturation, cytoskeletal rearrangement, physiology, migration during development, and host immune responses. These proteins bind to their corresponding 7-membrane G-protein-coupled receptors. Chemokines and their receptors are anti-inflammatory factors in autoimmune conditions, so consider as potential targets for neutralization in such diseases. They also express by cancer cells and function as angiogenic factors, and/or survival/growth factors that enhance tumor angiogenesis and development. Among chemokines, the CXCL12/CXCR4 axis has significantly been studied in numerous cancers and autoimmune diseases. CXCL12 is a homeostatic chemokine, which is acts as an anti-inflammatory chemokine during autoimmune inflammatory responses. In cancer cells, CXCL12 acts as an angiogenic, proliferative agent and regulates tumor cell apoptosis as well. CXCR4 has a role in leukocyte chemotaxis in inflammatory situations in numerous autoimmune diseases, as well as the high levels of CXCR4, observed in different types of human cancers. These findings suggest CXCL12/CXCR4 as a potential therapeutic target for therapy of autoimmune diseases and open a new approach to targeted-therapy of cancers by neutralizing CXCL12 and CXCR4. In this paper, we reviewed the current understanding of the role of the CXCL12/CXCR4 axis in disease pathology and cancer biology, and discuss its therapeutic implications in cancer and diseases.
Keywords: Autoimmune diseases; CXCL12/CXCR4 axis; Cancer; Chemokines; Signaling pathways; Targeted-therapy.
Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.Chin J Nat Med. 2018 Nov;16(11):801-810. doi: 10.1016/S1875-5364(18)30122-5. Chin J Nat Med. 2018. PMID: 30502762 Review.
-
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.Cancer Metastasis Rev. 2010 Dec;29(4):709-22. doi: 10.1007/s10555-010-9256-x. Cancer Metastasis Rev. 2010. PMID: 20839032 Free PMC article. Review.
-
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.Semin Cancer Biol. 2020 Oct;65:176-188. doi: 10.1016/j.semcancer.2019.12.007. Epub 2019 Dec 23. Semin Cancer Biol. 2020. PMID: 31874281 Review.
-
The good and bad faces of the CXCR4 chemokine receptor.Int J Biochem Cell Biol. 2018 Feb;95:121-131. doi: 10.1016/j.biocel.2017.12.018. Epub 2017 Dec 27. Int J Biochem Cell Biol. 2018. PMID: 29288743 Review.
-
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.Int J Clin Oncol. 2017 Dec;22(6):991-1000. doi: 10.1007/s10147-017-1187-x. Epub 2017 Oct 11. Int J Clin Oncol. 2017. PMID: 29022185 Review.
Cited by
-
Pig Milk Exosome Packaging ssc-miR-22-3p Alleviates Pig Intestinal Epithelial Cell Injury and Inflammatory Response by Targeting MAPK14.Int J Mol Sci. 2024 Oct 5;25(19):10715. doi: 10.3390/ijms251910715. Int J Mol Sci. 2024. PMID: 39409044 Free PMC article.
-
New insight into the role of fibroblasts in the epithelial immune microenvironment in the single-cell era.Front Immunol. 2023 Sep 22;14:1259515. doi: 10.3389/fimmu.2023.1259515. eCollection 2023. Front Immunol. 2023. PMID: 37809065 Free PMC article. Review.
-
Targeting CXCR4 in AML and ALL.Front Oncol. 2020 Sep 4;10:1672. doi: 10.3389/fonc.2020.01672. eCollection 2020. Front Oncol. 2020. PMID: 33014834 Free PMC article. Review.
-
VNS improves VSMC metabolism and arteriogenesis in infarcted hearts through m/n-AChR-Akt-SDF-1α in adult male rats.J Mol Histol. 2024 Feb;55(1):51-67. doi: 10.1007/s10735-023-10171-4. Epub 2024 Jan 2. J Mol Histol. 2024. PMID: 38165566 Free PMC article.
-
Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.Pharmaceutics. 2022 Jun 1;14(6):1189. doi: 10.3390/pharmaceutics14061189. Pharmaceutics. 2022. PMID: 35745762 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical